Oncologic Drugs Advisory Committee (ODAC)

Stories

FDA approves AstraZeneca's Etcamah for ESR1-mutated advanced breast cancer

As of September 2026: Voted 6-3 against camizestrant in April 2026; FDA overruled

The Food and Drug Administration approved AstraZeneca's pill Etcamah (camizestrant) on September 4, 2026, for people with metastatic breast cancer whose tumors carry an estrogen receptor-1 (ESR1) mutation. It is the first cancer therapy approved based on a resistance mutation found in blood before scans show the disease has progressed.

Updated Sep 9

FDA panel weighs blood-test-guided early drug switch for breast cancer

New Capabilities

As of May 2026: Reviewed camizestrant and Truqap applications on April 30, 2026

For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.

Updated May 31